Abstract
Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3319-3321 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 16 |
| Issue number | 13 |
| DOIs |
|
| State | Published - Jul 1 2010 |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'ADAM-17: A target to increase chemotherapeutic efficacy in colorectal cancer?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS